Tag:
Relovair
Latest Headlines
Latest Headlines
Elevation boasts 'gold standard' IIb data for COPD therapy
Today the biotech boasted that their therapy--EP-101--had registered positive data in a Phase IIb study, positioning it as a potential new "gold standard" in nebulized treatments for the ailment.
Novartis touts positive results for COPD inhalant
Novartis is reporting positive results from Phase III trials of QVA149, a COPD drug that uses the company's Breezhaler dry powder inhaler for delivery
GlaxoSmithKline undeterred by spotty results for Relovair
GlaxoSmithKline ( $GSK ) is pushing ahead with its plan to submit Relovair to regulators for approval this year.
UPDATED: GSK, Theravance share mixed bag of lung drug data ahead of FDA filing
GlaxoSmithKline and Theravance have dropped another up-and-down set of data related to development of their blockbuster hopeful Relovair.
Forest Labs notches victory en route to FDA ruling on COPD drug
Eyeing the major market for a chronic lung condition, Forest Laboratories ( $FRX ) picked up the backing of an FDA panel for its experimental COPD drug known as aclidinium. It's a key endorsement...
GSK will cut 3 R&D units, add 4 as DPU review triggers shakeup
Following a three-year review of its new approach to R&D, GlaxoSmithKline ( $GSK ) today revealed that it has decided to ax three of its 38 tightly-focused research units and add four more in a
PhRMA's COPD pipeline report spotlights blockbuster hopefuls
Anyone looking for a basic primer on experimental COPD drugs should check out PhRMA's latest compilation of new drugs in the pipeline. The big trade group found 54 COPD studies underway, which
Theravance shares tank on troubling study results for Relovair
by Suzanne Elvidge and John Carroll Shares of GlaxoSmithKline ( $GSK ) caught a chill this morning after investigators released mixed late-stage data and flagged troubling safety concerns for its COPD
GSK sets stage for big late-stage drug events, potential blockbusters
GlaxoSmithKline ( $GSK ) has taken some bold steps to reconfigure its R&D operations, tackling some of the productivity issues that have plagued Big Pharma groups. Over the next year, the
GSK relying on Ph3 strategy in R&D comeback bid
GlaxoSmithKline ($GSK) was one of the first of the Big Pharma companies to concede that its R&D effort needed to be completely revamped. Over the last couple of years GSK responded by breaking
